Correspondence 0001213900-23-030311 from Pasithea Therapeutics Corp. (KTTA)
Pasithea Therapeutics Corp.
Date: April 17, 2023 · CIK: 0001841330 · Accession: 0001213900-23-030311
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-271010
Letter
Pasithea Therapeutics Corp.
1111 Lincoln Road, Suite 500
Miami Beach, Florida 33139
Tel: (702) 514-4174
April 17, 2023
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Re: Pasithea Therapeutics Corp.
Registration Statement on Form S-3 (File No. 333-271010)
Filed on March 30, 2023
Ladies and Gentlemen:
Pasithea Therapeutics Corp. (the “Registrant”) hereby requests that the U.S. Securities and Exchange Commission (the “Commission”) take appropriate action to cause the above-referenced Registration Statement on Form S-3 to become effective on Wednesday April 19, 2023, at 4:05 p.m., Eastern Time, or as soon thereafter as is practicable or at such later time as the Registrant, or its representative, may orally request via telephone call to the staff of the Commission.
Please call James O’Grady of Lowenstein Sandler LLP at (646) 414-6849 to confirm the effectiveness of the Registration Statement or with any questions.
Very truly yours,
PASITHEA THERAPEUTICS CORP.
Show Raw Text
CORRESP
1
filename1.htm
Pasithea Therapeutics Corp.
1111 Lincoln Road, Suite 500
Miami Beach, Florida 33139
Tel: (702) 514-4174
April 17, 2023
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Re:
Pasithea Therapeutics Corp.
Registration Statement on Form S-3 (File No. 333-271010)
Filed on March 30, 2023
Ladies and Gentlemen:
Pasithea Therapeutics Corp. (the
“Registrant”) hereby requests that the U.S. Securities and Exchange Commission (the “Commission”) take appropriate
action to cause the above-referenced Registration Statement on Form S-3 to become effective on Wednesday April 19, 2023, at 4:05
p.m., Eastern Time, or as soon thereafter as is practicable or at such later time as the Registrant, or its representative, may orally
request via telephone call to the staff of the Commission.
Please call James O’Grady
of Lowenstein Sandler LLP at (646) 414-6849 to confirm the effectiveness of the Registration Statement or with any questions.
Very truly yours,
PASITHEA THERAPEUTICS CORP.
By:
/s/ Tiago Reis Marques
Name:
Tiago Reis Marques
Title:
Chief Executive Officer